RNA SEQUENCE ANALYSIS OF THE E2 GENES OF WILDTYPE AND NEUROATTENUATED MUTANTS OF MHV-4 REVEALS A HYPERVARIABLE DOMAIN

Suezanne E. Parker and Michael J. Buchmeier

Department of Neuropharmacology Scripps Clinic and Research Foundation La Jolla, CA

INTRODUCTION

Murine hepatitis virus 4 (MHV-4) is a neurotropic coronavirus (1-4). Infection of the CNS in susceptible mice strains results in a fatal encephalitis with destruction of neurons accompanied by demyelination. The few mice that survive the acute infection develop a chronic demyelinating disease characterized by episodes of demyelination followed by remyelination (2,5). The extensive white matter disease is believed to arise as the consequence of viral infection and destruction of oligodendrocytes (2,3,6).

There is substantial evidence indicating that the MHV-4 E2 glycoprotein plays a crucial role in determining the neurovirulence of an MHV-4 infection. E2, the major constituent of the viral spike or peplomer (7,8), is initially synthesized as a 180 kDa peripheral membrane glycoprotein and is subsequently cleaved into two non-identical 90 kDa subunits compromising the amino terminal (S_1 or 90B) and the carboxy terminal (S_2 or 90A) regions of the protein (9). The E2 glycoprotein mediates the attachment of the virion to susceptible cells, is responsible for cell to cell fusion after infection and is the major target on the virus for neutralizing antibodies (9-12). Passive transfer of neutralizing MAbs to E2 alters the course of MHV-4 induced disease from a fatal encephalitis to a chronic demyelinating disease (13). Furthermore, variants of MHV-4 selected for their ability to escape neutralization by anti-E2 MAbs are neuroattenuated and induce chronic demyelination (14-16).

The selection of neuroattenuated variants by antibodies specific for E2 provides some of the strongest evidence that E2 plays a pivotal role in the outcome of a CNS infection. To localize the genetic alteration(s) in E2 responsible for neuroattenuation we have sequenced the viral RNA encoding the E2 gene of MHV-4 and of the neuroattenuated variants. The carboxy terminal half of E2 was found to be highly conserved whereas in contrast, the amino terminal half is very polymorphic and contains deletions of up to 159 amino acids in the antibody resistant variants.

METHODS

The parental strain of MHV-4 was originally obtained from L.P. Weiner and propagated on Sac- cells as previously described (7). Neuroattenuated variants V5A13.5(86) and V4B11.3(86) were isolated from a 1986 plaque purified stock of MHV-4 by their ability to resist neutralization by MAb 5A13.5 (epitope E2B) and 4B11.6 (epitope E2C) respectively, as previously described (14). V5A13(88) was recently isolated from a 1988 plaque purified stock of MHV-4 (17). JHM-X, a variant of MHV-JHM which has been shown to have a smaller E2 gene as well as a truncated E2 glycoprotein compared to wildtype (18) was kindly provided for sequence analysis by Dr. M.M.C. Lai.

The sequence of the viral RNA was determined by the dideoxy primer extension method using radiolabeled synthetic oligonucleotides 20 bases in length as primers (19,20). Viral RNA was isolated from infected cells by guanidine isothiocyanate extraction (21). Sequence data was compiled and analyzed using the University of Wisconsin Genetics Computer Group sequence analysis software package (22).

RESULTS AND DISCUSSION

Direct RNA sequence analysis of the E2 gene of the neuroattenuated variants of MHV-4 and the JHM-X revealed that the variants had large deletions ranging in size from 426 to 477 nucleotides in the 5' coding region of the E2 gene. As a consequence of the nucleotide deletions, the E2 glycoproteins of the variants have large deletions ranging from 142 amino acids in the case of V5A13.1(86) to 159 amino acids in the case of V4B11.3(86). Table 1 lists the size and location of the deletions. As a consequence of the deletion in the E2 glycoprotein of V5A13.1(86), there is a lysine to asparagine substitution at amino acid 433 at the 5' boundary of the deletion (Fig. 1). The deletions in E2 all map to a localized region in the amino terminal half of the protein (Fig. 1) thus defining the location of major epitopes determining both neutralization and neurovirulence.

Virus	Nucleotide Deletion	Amino Acid Deletion
MHV-JHM	423 (1,359-1,781)	141 (454-594)
JHM-X	458 (1,336-1,794)	153 (446-598)
V5A13.1(86)	426 (1,298-1,723)	142 (434-575)
V5A13(88)	447 (1,307-1,753)	149 (436-585)
V4B11.3(86)	477 (1,285-1,761)	159 (429-586)

Table 1. Location of Deletions in E2



Fig. 1. Hydropathicity plot of the MHV-4 E2 glycoprotein according to the analysis of Kyte and Doolittle (40) and localization of the deletions in the amino terminal domain of MHV-4 E2. The vertical scale is the average hydropathicity (+2 to -2) index for each residue over a window of 9 amino acids. Hydrophobic sequences appear above the midline and hydrophilic sequences appear below the midline. Below is an alignment of comparable amino acid sequences from MHV-JHM (29), JHM-X, and MHV-4 variants V&A13.1(86), V4B11.3(86) and V5A13(88). The numbering is relative to the MHV-4 E2 amino acid sequence. Dots indicate deletions and boxed amino acids indicate sequence changes from MHV-4 E2. The signal sequence, putative cleavage site and transmembrane domains of E2 are indicated.

Selection by MAbs of viral escape mutants with large deletions is uncommon. Most often it has been shown that MAb selected variants have point mutations which affect antibody binding to a given epitope (23-28). The E2 glycoprotein may be unique in that it can accommodate large deletions while retaining functions necessary for virus growth both in vitro and in vivo.

A comparison of the amino acid sequence of E2 for our parental strain of MHV-4 (see Fig. 2 for the complete sequence of E2 for MHV-4) with that of MHV-JHM (29), and of MHV-A59 (30) reveals that the carboxy terminal region is highly conserved whereas the amino terminal region of E2 is very heterogeneous with respect to size. Of importance is the finding that the E2 glycoprotein of MHV-4 contains an additional 141 amino acids (aa 454-594) as compared to MHV-JHM (Fig. 2). This clearly demonstrates that MHV-4 and MHV-JHM which were previously considered to be synonymous, are in fact distinct viruses. Given the near sequence identity of E2 for the two viruses, MHV-JHM may actually be a deletion variant of MHV-4. The E2 glycoprotein of MHV-4 also contains an additional 52 amino acids (501-552) compared to MHV-A59. This heterogeneity in E2 maps to the same region of the protein which is deleted in the variants of MHV-4 (Fig. 2). Heterogeneity in terms of size of E2 has also been reported to occur as a result of the $\underline{in \ vitro}$ and in vivo passage of MHV where variants with both a smaller E2 (31) as well as variants with a larger E2 than the parental strain have been described (32,33). As the sequence data becomes available for these variants it will be of interest to determine if these differences represent deletions or insertions of the polymorphic sequences that we have described.

	TAATCTAAAC	
1	 . т е	40
ATGCTGTTCGTCTTTATTTTACTATTACCCTCTTGTTTAGGUTATTATTGGTGATTTTAGATGTATCCAGACCGTGAATTATAACGGCAATAATGCTTCTGCGCCTAGCAT	TTAGCACCGAA	120
avduskalatvutopuviklatiiitevvevosnyk	 NLA	80
GCAGTCGATGTTTCCAAAGGTCTGGGCACTTACTATGTTTTAGATCGTGTTTACTTAAATGCCACGTTATTGCTTACTGGTTATTATCCTGTGGGACGGTTCCAATTATCC	GGAATCTCGCG	240
L T G T N T L S L T W F K P P F L S E F N D G I F A K V Q N L K T N T P T CITACAGGCACTAATACCTTAAGCCTTACGTGGTTTAAACCACCCCTTTCTAAGTGAGTTTAATGATGGTATATTGGTAAGGTCCAGGAACCTCAAGACAAATACGCCAAC	G A T CAGGTGCAACC	360
<u>.</u>		
		160
		400
PYTPCKPNTNGNRVIGFWHTDVKPPICLLKR <mark>N</mark> FTFNV	N A P	200
CCTTACACACCCCTGTAAGCCTAATACCAATGGTAATCGTGTTATTGGATTTTGGCACACAGATGTCAAACCGCCGATTTGTCTTTTAAAGCGTAATTTACGTTTAATG	ITAATGCCCCT	600
W L Y F H F Y Q Q G G T F Y A Y Y A D K P S A T T F L F S V Y I G D I L T	QYF	240
TGGCTTTATTTCCATTTTTATCAGCAGGGTGGTACTTTTTATGCGGACAAACCTTCCGGCTACTACGGTTTTTGTTTAGTGTGTATATTTGGCGACATTTTAA	CACAGTATTTT	720
VLPFICTPTAGSTLLPLYWVTPLLKRQYLFNFNEKGV	 іт s	280
GTGTTACCTTTTATTTGTACTCCAACAGCTGGTAGCACTTTACTGCCGCTCTATTGGGTTACACCTTTACTTAAGCGCCAATATTTGTTTAATTTAATGAAAAGGGTG	TCATTACTAGT	840
		3 20
GCTGTTGATTGCGCCAGCAGCTACATTAGTGAAATAAAATGTAAGACCCAAAGTCTCTTACCGAGTACTAGTGTCTATGATCTATCCGGTACAACGGTCCAACCTGTTGC	GAGTTGTGTAC	960
R R V P N L P D C K I E E W L T A K S V P S P L N W E R R T F Q N C N F N	L S S	360
	· · ·	
LLRYVQAESLSCNNIDASKVYGMCFGSVSVDKFAIPR	SRQ	400
	JAAGCCGTCAA 1	1200
IDLQIGNSGFLQTANYKIDTAATSCQLYYSLPKNNVT	INN	440
ATTGATTTACANATTGGCAACTCCGGATTTTTGCAAACGGCTAATTATAAGATTGATACCGCTGCCACATCATGTCAGCTGTATEACAGTCTTCCTAAGAATAATGETAC	CCATAAATAAC 1	1320
· JHMX· · · · · · · · · · · · · · · · · · ·	 УСЕ	480
TATAACCCCTCGTCTEGGAATAGGAGGTATGGTTTTAAEGATGCTGGTGTGTTTGGCAAAAGTAAACATGATGTTGCCTACGCCCAGCAATGTTTTACTGTGCGACCTAG	GCTATTGTCCG 1	1440
A59		
TGTGCACAACCGGACATAGTTAGCGCTTGCACTAGTCCGACCCAAACCCATGCTGCTTCTTGGAATGGCCCCACAGGCACAATCATCATCGTGGAGTGTTCTCTTTGGAATGGGCCCC	L R S ATTTGCGCTCG 1	520 1560
A59		
A R V G S G T Y T C E C T C K P N P F D T Y D L R C G Q I K T I V N V G D	HCE	560
V5A (86) V5A (88) V4B (86) JHM	JHMX .	1680
G L G V L E D K C G N S D P H K G C S C A N D S F I G W S H D T C L V N D	RCQ	600
GGTCTGGGTGTTTTAGAAGATAAATGTGGGCAATAGCGATCCACATAAGGGCTGTTCTTGTGCCAATGATTCTTTTATCGGATGGTCACATGACACTTGTTTAGTAAATGJ	ATCGCTGCCAA 1	800
IFANILLNGINSGTTCSTDLQLPNTEVATGVCVRYDL	 У G I	640
attitigctaacatattgttaaatggcattaatagtgggactacgtgttccacagatttacaattgcctaatactgaagtggccactggcgtttgcgtcagatatgacct	ICTATGGTATT 1	920
T 6 0 6 V P K F V K A F V V P C P A A A A A A A A A A A A A A A A A		
ACTGGTCAAGGTGTTTTTAAAGAGGTCAAGGCTGACTATTATAAAGCTGGCAGGCCCTATTATATGATGTTAATGGTAACTTAAACGGGTTCCGTGACCTTACCACTA	јк ту Асладасттат 2	2040
T I R S C Y S G R V S A A Y H K E A P E P A L L Y R N I N C S Y V F T N N ACGATAAGGAGCTGTTATAATGGCCGTGTTTTCTGCTGCATATAAGAAGAACCACCCAAACCGCTTTCTGCTTATAATAAGAAGCAACCACAAAGAACCACACACAAAGAACCACACACAAAGAACCACACACACACACACACACACACACACACACACACAC	JISR	720
	ATATTTCCCGT 2	2100
E E N P L N Y F D S Y L G C V V N A D N R T D E A L P N C D L R M G A G L		
	 с v р	760
GAGGAAAACCCCCCTTAACTATTTGATAGTTATTTGGGTTGTGTTGTTGATGATGACCGCACGGATGAGGCGCTTCCTAATTGCGATCTCCGTATGGGTGCTGGGTGCTGGAC	CVD TATGCGTAGAT 2	760 2280
GAGGAAAACCCCCTTAACTATTTGAATAGTTATTGGGGTGTGTGT	 C V D TATGCGTAGAT 2 L Y E	760 2280 800
GAGGAAAACCCCCTTAACTATTTGAATAGTTATTGGGGTGGTGTGTGT	C V D TATGCGTAGAT 2 L Y E SATTATATGAG 2	760 2280 800 400
GAGGAAAACCCCCTTAACTATTTGAATAGTTATTGGGGTGGTGTGTGT	CVD TATGCGTAGAT 2 LYE GATTATATGAG 2	760 2280 800 400
GAGGAAAACCCCCCTTAACTATTTGGATAGTTATTTGGGTTGTGTGTG	. C V D TATGCGTAGAT 2 L Y E SATTATATGAG 2 C R Q ZATGCAGACAG 2	760 2280 800 400 840 520
GAGGAAAACCCCCTTAACTATTTGAATAGTTATTTGGGTTGTGTGTG	CVD TATGCGTAGAT2 LYE SATTATATGAG2 CRQ CATGCAGACAG2	760 2280 800 400 840 520
GAGGAAAACCCCCTTAACTATTTGATAGTTATTTGGGTTGTGTGTG	C V D TATGCGTAGTA 2 L Y E SATTATATGAG 2 C R Q CATGCAGACAG 2 V T I	760 2280 800 400 840 520 880 8640
GAGGAAAACCCCCTTAACTATTTGATAGTTATTTGGGTTGTGTGTG	C V D TATGCGTAGAT 2 L Y E SATTATATGAG 2 C R Q CATGCAGACAG 2 V T I JTGTTATCATA 2	760 2280 800 400 840 2520 880 2640
GAGGAAAACCCCCCTTAACTATTTGATAGTTATTTGGGTTGTGTGTG	C V D TATGGGTAGAT 2 L Y E SATTATATGAG 2 C R Q CATGGCAGACAG 2 V T I JTGTTACTATA 2 I R G	760 2280 800 400 840 2520 880 2640 920

Recombination between heterologous strains of coronaviruses has been reported to occur at a relatively high frequency (34-36) and is believed to occur as a consequence of the discontinuous mechanism of "leader primed transcription" that has been described for MHV replication. Presumably, during MHV replication RNA transcription frequently pauses at sites of secondary structure on the template RNA releasing the transcriptional complex and the nascent RNA strand which subsequently rejoins the template and re-initiates transcription (37). Deletions of genomic RNA could occur by the same mechanism whereby the transcriptional complex reinitiates at a distant site on the template RNA from where the initial disassociation event occurred. Because E2 can accommodate large deletions, the progeny virions resulting from a recombination in the E2 may require site specific recombination without the accompanying loss of genetic information.

R	s	A	I	Е	D	L	L	F	D	ĸ	v	к	L	s	D	v	G	F	٧	Е	A	Y	N	N	с	т	G	G	Q	E	v	R	D	L	L	с	v	Q	s	960
co	TT	AGC	ГАТ	AGA	GGAT	TTA	ATT.	ATT	TGA	CAA	GGT	CAAP	CT/	ATC	TGA	CGT	TGG	CTT	TGT	GAG	GCT	TAT	AA	CAAT	TGO	CAC	TGG	rgg1	CAP	GAA	GTI	cGC	GAC	ст	CTT	TGO	CGTA	ACAG	TCT	2880
F	N	G	T	ĸ	v	r.	P	p	v	т.	s	E	c	0		c	6	v	т		c	2	T	2	2		м	F	ъ.	ъ	w	т	÷			د	v	ъ		1000
		meer								~~~~	~ ~ ~	-		N.C.N.		-														-	-	1					•			2000
11	TA	TGGG	CAT	CAA	AGTA		ACC	rcc	CGI	61 T	GIC	TGAC	AG	I'CA	AAT	crc	TGG	CTA	CAC	AGC C	663	rger	AC:	raca	GC	AGC	TAT	GTT	ccr	CCT	TGG	JACI	GCF	(GC:	rgen	GG	rere	JCCA	wrrc.	3000
			·			•				•			·			•							•			•			•				•			٠			•	
s	L	N	۷	Q	Y	R	I	N	G	L	G	v	т	м	N	v	L	s	E	N	Q	к	м	I	A	s	A	F	N	N	A	L	G	A	I	Q	Е	G	F	1040
A	STT:	AAA?	TGT	TCA	ATAT	AGO	SAT	таа	TGG	TTT	AGG	TGTO	CACI	[AT	GAA	TGT	TCT	TAG	TGAG	GAAC	CN	AAG	AT	GAT?	rGC:	TAG	TGC	TTT	raa(AAC	GCC	GCTC	GGT	GC	TAT	CAO	GGAA	١GGĆ	TTC	3120
D	A	т	N	s	A	L	G	к	I	Q	s	v	v	N	A	N	A	Е	А	L	N	N	L	L	N	Q	L	s	N	R	F	G	A	I	s	А	s	L	Q	1080
GJ	TG	AAC	саа	TTC	тост	сти	AGG	таа	GAT	CCA	бтс	CGT	FGT	ГАА [,]	TGC		cgc	TGA	AGC	ACTT	TAAT	FAAT	тт	ATT		CCA	АСТ	TTC	FAAT	AGG		rGG1	GCT	ГАТ	TAG	rgc	TTCT	LTT!		3240
			÷			. ·				•													_										÷		~				• •	1120
E	1	L	T	к		D	A	v	E	A	ĸ	A	Q	1	D	R	L	1	N	G	ĸ	L.	T	A	Ľ.	N	^	x	÷	s	ĸ	Q	L	5			- T		1	1120
GJ	AAA'	TCT.	AAC	GCG	GCTI	GAO	CGC	TGT	AGA	AGC	AAA	GGC	CCAG	GAT.	AGA	TCG	тст	TAT	TAA	rGGG	CAGO	STT?	AC.	TGC	ACT	TAA	TGC	GTA	TAT?	TCC	:AAC	GCA	ACTO	CAG	TGA	r AG	FACO	JCTT	TATT	3360
			÷			•				•			÷			•				•			·										·			·			•	
к	F	s	A	A	Q	А	I	Е	к	۷	N	Е	с	۷	к	s	Q	т	т	R	I	N	F	с	G	N	G	N	н	I	L	s	L	۷	Q	N	A	Р	Y	1160
A	AT'	TAG	TGC	TGC	TCAG	GCO	CAT	CGA	АЛА	GGT	CAA	TGAG	GTG	CGT	таа	GAG	CCA	AAC	TAC	SCGG	TAT:	TAAT	TT	CTG	rGG	CAA	TGG	TAA	TCAG	:ATA	TT	ATC	ACT1	rgt	CCAG	GAA	TGCC	SCC?	TAT	3480
G	T.	c	F	т	н	F	s	v	v	p	т	s	F	к	т	A	N	v	s	p	G	T.	c	т	s	G	D	R	G	L	A	Р	к	А	G	Y	F	v	0	1200
							~~~	-								~~~~				•				-	-	-	-		-	-		-			-		-	-		3600
G	act	INIG	111	TAI	TCAL	110	CAG	CIN	ice i	GUU	AAC	ALC	C11	IAA	AAC		AAA	IGI	GAG	rcc:	ruu	ACT	ALC:		110	100	I GA	I AG.	1001		idc.	NCC.		NUC	100.			101	I CAA	3000
			•			·				•			·			•				•			·	A						•	_		·			•			·	
D	N	G	Е	w	к	F	т	G	s	N	Y	Y	¥	Ρ	Ę	₽	I	т	D	к	N	s	v	v	м	I	s	с	A	v	N	Y	т	ĸ	A	Ρ	Е	۷	F	1240
G.	ATA	ATGG	AG A	\GTG	GAAC	TT	CAC	AGG	CAG	TAA	TTA	TTA	CTA	ccc	TGA	ACC	CAT	TAC.	AGA	TAA	<b>A</b> AA'	TAG	GT	TGT	CAT	GAT	CAG	TTG	CGC	GTO	GAA'	TTA	CAC	AAA	AGC	SCC	TGA	AGT:	TTTC	3720
L	N	N	s	I	Р	N	L	Р	D	F	к	Е	E	L	D	к	w	F	к	N	0	т	s	I	A	P	D	L	s	L	D	F	E	к	L	N	v	т	F	1280
<b>T</b>	TGA	1 - 1 1 - 1	сто		1			-		CTT	• <b>T</b> A A	GGA	GGA	GTT	AGA	таа	ATG	GTT	TAA	GAA'	- FCA	GAC	TC	тат	TGC	GCC	TGA	ттт	ATC	CT	GA	TTT	CGA	GAA	GTT	AAA	TGT	TAC	TTTC	3840
•	1010							nee										••••																						
			•			•			_	•			÷					-	_	•			÷					_		•			÷							1 2 2 0
L	D	L	т	¥	E	M	N	R	I	Q	D	А	I	ĸ	ĸ	L	N	Е	s	¥	I	N	L	ĸ	E.	v	G	т	Y	E	M	¥	v	ĸ	w	P	w	x	v	1320
C	TGG.	ACCT	GAC	TTA	TGAC	AT	GAA	CAC	GAT	TCA	GGA	TGC.	AAT	ТАА	GAA	GTI	AAA	TGA	GAG	CTA	CAT	CAA	сст	CAA	GGA	AGT	rtgg	CAC	ATA	<b>FGA</b>	AT	GTA	TGT	GAA	ATG	GCC	TTG	GTA	TGTT	3960
w	L	L	I	G	L	А	G	v	A	v	с	v	L	L	F	F	I	с	с	с	т	G	с	G	s	с	с	F	R	ĸ	с	G	s	с	с	D	Е	¥	G	1360
т	GGT	rg <i>C</i> T		TGG	TTT	GC	TGO	TGT	AGC	CGT	TTG	TGT	GTT	АТТ	ATT	CTT	TAT	ATG	TTG	CTG	CAC	AGG	гтG	CGG	CTC	ATC	TTG	TTT	TAG.		ATG	CGG.	AAG	TTG	TTG	TGA	TGA	GTA	TGGA	4080
ê																	•									-					-									
			÷		-		_			•	_		÷	-																										
G	н	Q	D	s	I	v	I	н	N	I	s	A	н	ε	D					13	/6																			
~	C . C		~~ .		m > mn	C.T.	C 3 7		T > >	TAT	-		CON	TCA	CCA	TTO	LACT	'ATC	ACA.	41	20																			

- ACCAGGACAGTATTGTGATACATAATATTTCAGCCCATGAGGATTGACTATCACA 4139
- Fig. 2. Nucleotide and predicted amino acid sequence of the MHV-4 E2 gene. The numbering starts at the ATG codon. Open circles indicate the N-terminal signal sequence (calculated according to the algorithm of Von Heijne [38], as described by Fazakerley and Ross [39]) and closed circles indicate the hydrophobic carboxyterminal transmembrane domain. Potential glycosylation sites are indicated by boxed asparagine residues. The intergenic homology sequence TAATCTAAAC is boxed. The putative proteolytic cleavage site between the amino terminal and carboxy terminal domain is indicated by an arrowhead. The MHV-JHM amino acid sequence (29) is indicated where differences occur. Brackets denote the boundaries of the deletion for the indicated viruses.

By direct RNA sequence analysis of the E2 gene of wildtype MHV-4 and of neuroattenuated variants we have demonstrated that the E2 glycoprotein of MHV is very heterogeneous with respect to deletions in a localized region of the amino terminal half of the protein. Sequences localized within this polymorphic region of the protein are important in determining the neurovirulence of an MHV-4 infection of the CNS. Studies are currently underway to further assess the role of this domain in an <u>in vivo</u> infection.

## ACKNOWLEDGMENTS

The authors thank Maria Salvato and Elaine Shimomaye for advice on RNA sequencing, Joseph O'Neill for technical assistance and Gay Schilling for manuscript preparation. This work was supported by NIH grants AI-25913 and NS-12428. SEP was the recipient of a National Multiple Sclerosis Society Fellowship. This is Publication Number 5971-IMM from the Department of Neuropharmacology, Research Institute of Scripps Clinic, La Jolla, CA 92037.

## REFERENCES

- L.P. Weiner, Pathogenesis of demyelination induced by a mouse hepatitis virus (JHM virus), <u>Arch. Neurol</u>. 28:298 (1973).
- P.W. Lampert, J.K. Sims, and A.J. Kniazeff, Mechanism of demyelination in JHM virus encephalomyelitis, Electron microscopic studies, <u>Acta</u>. <u>Neuropathol</u>. 24:76 (1973).
- M.V. Haspel, P.W. Lampert, and M.B.A. Oldstone, Temperature sensitive mutants of mouse hepatitis virus produce a high incidence of demyelination, <u>Proc. Natl.</u> <u>Acad. Sci. USA</u> 75:4033 (1978).
- H. Wege, S. Siddel, and V. ter Meulen, The biology and pathogenesis of coronaviruses, <u>Curr. Top. Microbiol</u>. <u>Immunol</u>. 99:165 (1982).
- 5. R.L. Knobler, P.N. Tunison, P.W. Lampert, and M.B.A. Oldstone, Selected mutants of mouse hepatitis virus type 4 (JHM strain) induce different CNS diseases, <u>Am</u>. J. <u>Pathol</u>. 109:157 (1982).
- 6. M.E. Dubois-Dalcq, E.W. Doller, M.V. Haspel, and K.V. Holmes, Cell tropism and expression of mouse hepatitis virus (MHV) in mouse spinal cord cultures, <u>Virology</u> 119:317 (1982).
- L.S. Sturman, K.V. Holmes, and J. Behnke, Isolation of coronavirus envelope glycoproteins and interaction with the viral nucleocapsid, <u>J. Virol</u>. 33:449 (1980).
- S. Siddel, H. Wege, and V. ter Meulen, The structure and replication of coronaviruses, <u>Curr. Top. Microbiol</u>. <u>Immunol</u>. 99:131 (1982).
- S. Sturman, C.S. Ricard, and K.V. Holmes, Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: Activation of cell-fusing activity of virions by trypsin and separation of two different 90K cleavage fragments, <u>J. Virol</u>. 56:904 (1985).
- 10. A.R. Collins, R.L. Knobler, H. Powell, and M.J. Buchmeier, Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell-cell fusion, <u>Virology</u> 119:358 (1982).

- 11. P.J. Talbot, A.A. Salmi, R.L. Knobler, and M.J. Buchmeier, Topographical mapping of epitopes on the glycoproteins of murine hepatitis virus-4 (strain JHM): Correlation with biological activities, <u>Virology</u> 132:250 (1984).
- 12. H. Wege, R. Dorries, and H. Wege, Hybridoma antibodies to the murine coronavirus JHM: Characterization of epitopes on the peplomer protein (E2), <u>J. Gen. Virol</u>. 65:1931 (1984).
- 13. M.J. Buchmeier, H.A. Lewicki, P.J. Talbot, and R.L. Knobler, Murine hepatitis virus-4 (strain JHM)-induced neurological disease is modulated <u>in vivo</u> by monoclonal antibody, Virology 132:261 (1984).
- monoclonal antibody, <u>Virology</u> 132:261 (1984).
  14. R.G. Dalziel, P.W. Lampert, P.J. Talbot, and M.J. Buchmeier, Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence, <u>J. Virol</u>. 59:463 (1986).
- 15. J.O. Fleming, M.D. Trousdale, F.A.K. El-Zaatari, S.A. Stohlman, and L.P. Weiner, Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies, J. <u>Virol</u>. 58:869 (1986).
- 16. H. Wege, J. Winter, and R. Meyermann, The peplomer protein E2 of coronavirus JHM as a determinant of neurovirulence: Definition of critical epitopes by variant analysis, J. <u>Gen. Virol.</u> 69:87 (1988).
- 17. T.M. Gallagher, S.E. Parker, and M.J. Buchmeier, Neutralization resistant variants of a neurotropic coronavirus are generated by deletions within the amino terminal portion of the E2 spike glycoprotein, <u>J</u>. <u>Virol</u>. submitted (1989).
- 18. F. Taguchi and J.O. Fleming, Comparison of six different murine coronavirus JHM variants by monoclonal antibodies against the E2 glycoprotein, <u>Virology</u> 169:233 (1989).
- 19. P.H. Hamlyn, M.J. Gait, and C. Milstein, Complete sequence of an immunoglobulin mRNA using specific priming and the dideoxynucleotide method of RNA sequencing, <u>Nuc. Acids Res</u>. 9:4485 (1981).
- F. Sanger, S. Nicklen, and A.R. Coulson, DNA sequencing with chain terminating inhibitors, <u>Proc. Natl. Acad.</u> <u>Sci. USA</u> 74:5463 (1977).
- 21. J.M. Chirgwin, A.E. Przybyla, R.J. MacDonald, and W.J. Rutter, Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease, <u>Biochemistry</u> 18:5294 (1979).
- J. Devereux, P. Haberli, and O. Smithies, A comprehensive set of sequence analysis programs for the VAX, <u>Nuc. Acids Res</u>. 12:387 (1984).
   D.M.A. Evans, P.D. Minor, G.S. Schild, and J.V. Almond,
- 23. D.M.A. Evans, P.D. Minor, G.S. Schild, and J.V. Almond, Critical role of an eight-amino acid of VP₁ in neutralization of poliovirus type 3, <u>Nature</u> 304:459 (1983).
- 24. I. Seif, P. Coulon, S.E. Rollin, and A. Flamand, Rabies virulence: Effect on pathogenicity and sequence characterization of rabies virus mutations effecting antigenic site III of the glycoprotein, <u>J. Virol</u>. 53:926 (1985).
- 25. J.W. Yewdell, A.J. Caton, and W. Gerhard, Selection of influenza A virus adsorptive mutant by growth in the presence of a mixture of monoclonal anti-hemagglutinin antibodies, <u>J. Virol</u>. 57:623 (1986).

- 26. R. Bassel-Duby, D.R. Spriggs, K.L. Tyler, and B.N. Fields, Identification of attenuating mutations on the reovirus type 3¹ double-stranded RNA segment with a rapid sequencing technique, <u>J. Virol</u>. 60:64 (1986).
- 27. S.D. Thompson and A. Portner, Localization of functional sites on the hemagglutinin-neuraminidase glycoprotein of Sendai virus by sequence analysis of antigenic and temperature-sensitive mutants, <u>Virology</u> 160:1 (1987).
- 28. L. Luo, Y. Li, R.M. Snyder, and R.R. Wagner, Point mutations in glycoprotein gene of vesicular stomatitis virus (New Jersey serotype) selects resistance to neutralization by epitope-specific monoclonal antibodies, <u>Virology</u> 163:341 (1988).
- antibodies, <u>Virology</u> 163:341 (1988). 29. I. Schmidt, M. Skinner, and S. Siddel, Nucleotide sequence of the gene encoding the surface projection glycoprotein of coronavirus MHV-JHM, <u>J. Gen. Virol</u>. 68:47 (1987).
- 30. W. Luytjes, L.S. Sturman, P.J. Bredenbeek, J. Charite, B.A.M. van der Zeijst, M.C. Horzinek, and W.J.M. Spaan, Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site, <u>Virology</u> 161:479 (1987).
- 31. V.L. Morris, C. Tieszer, J. Mackinnon, and D. Percy, Characterization of coronavirus JHM variants isolated from Wistar Furth rats with a viral induced demyelinating disease, <u>Virology</u> 169:127 (1989).
- F. Taguchi, S.G. Siddel, H. Wege, and V. ter Meulen, Characterization of a variant virus selected in rat brains after infection by coronavirus mouse hepatitis virus JHM, <u>J. Virol</u>. 54:429 (1985).
   F. Taguchi, P.T. Massa, and V. ter Meulen, Characteriza-
- 33. F. Taguchi, P.T. Massa, and V. ter Meulen, Characterization of a variant virus isolated from neural cell culture after infection of mouse coronavirus JHMV, <u>Virology</u> 155:267 (1986).
- 34. M.M.C. Lai, R.S. Baric, S. Makino, J.G. Keck, J. Egberg, J.L. Leibowitz, and S.A. Stohlman, Recombination between nonsegmented RNA genomes of murine coronaviruses, J. <u>Virol</u>. 56:449 (1985).
- 35. S. Makino, J.G. Keck, S.A. Stohlman, and M.M.C. Lai, High frequency of RNA recombination of murine coronaviruses, <u>J. Virol</u>. 57:729 (1986).
- 36. J.G. Keck, G.K. Matsushima, S. Makino, J.O. Fleming, D.M. Vannier, S.A. Stohlman, and M.M.C. Lai, <u>In vivo</u> RNA-RNA recombination of coronavirus in mouse brain, J. Virol. 62:1810 (1988).
- 37. R.S. Baric, C.-K. Chien, S.A. Stohlman, and M.M.C. Lai, Analysis of intracellular small RNAs of mouse hepatitis virus: Evidence for discontinuous transcription, <u>Virology</u> 156:342 (1987).
- 38. G. von Heijne, A new method for predicting signal sequence cleavage sites, <u>Nuc. Acids Res</u>. 14:4683 (1986).
- 39. J.K. Fazakerley and A.M. Ross, Computer analysis suggests a role for signal sequences in processing polyproteins of enveloped RNA viruses and as a mechanism of viral fusion, <u>Virus</u> <u>Genes</u> 2:219 (1989).
- 40. J. Kyte and R.F. Doolittle, A simple method for displaying the hydropathic character of a protein, <u>J</u>. <u>Mol. Biol</u>. 157:105 (1982).